Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 9/20 | 0.50 |
| ▸ | RAB9A | P51151 | 9/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.50 |
| ▸ | PKM | P14618 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12859635 | 0.85 | SMN1; SMN2 (0.52) | TP53NPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL1192656 | 0.84 | ATR (0.50) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL30953487 | 0.84 | ATR (0.50) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL8670718 | 0.84 | FDPS (0.50) | — | |
| SCHEMBL10276435 | 0.83 | TP53 (0.60) | TP53NPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL30633355 | 0.83 | ATR (0.46) | — | |
| SCHEMBL437390 | 0.83 | ATR (0.52) | MAPK10MAPT | |
| SCHEMBL7909650 | 0.83 | ATR (0.46) | — | |
| SCHEMBL1133582 | 0.83 | ATR (0.46) | NPC1RAB9ASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL29402022 | 0.83 | ATR (0.46) | TP53NPC1RAB9ASMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260043029-A1 | RNAi Agents for Inhibiting Expression of Thymic Stromal Lymphopoietin (TSLP), Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4665355-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF THYMIC STROMAL LYMPHOPOIETIN (TSLP), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4658788-A2 | OPTIMIZED RNAI AGENTS FOR INHIBITING EXPRESSION OF CORONAVIRUS (COV) VIRAL GENOMES, COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12486502-B2 | RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4648782-A1 | RNAI AGENTS FOR INHIBITING INFLUENZA A VIRAL GENE EXPRESSION, COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250214931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-20250034578-A1 | Subcutaneous Delivery of RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products | Arrowhead Pharmaceuticals, Inc. | 2025-01-30 | — | — | US | disclosed |
| EP-4496579-A2 | SUBCUTANEOUS DELIVERY OF RNAI AGENTS FOR INHIBITING EXPRESSION OF RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS (RAGE) | Arrowhead Pharmaceuticals, Inc. (US) | 2025-01-29 | — | — | EP | disclosed |
| US-12084414-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4419689-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF MATRIX METALLOPROTEINASE 7(MMP7), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| WO-2001087854-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001074811-A2 | SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-11 | — | — | WO | disclosed |
| WO-2000069834-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | disclosed |
| EP-0866705-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1999-03-03 | — | — | EP | disclosed |
| US-5852045-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0866705-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997014417-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-04-24 | — | — | WO | disclosed |
| EP-0099770-B1 | OXAZINOBENZOTHIAZINE-6,6-DIOXIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENT | PROVESAN S.A. (CH) | 1986-08-27 | — | — | EP | disclosed |
| US-4563452-A | ANTIINFLAMMATORY, ANALGESIC | PROVESAN S.A. (CH) | 1986-01-07 | — | — | US | disclosed |
| EP-0099770-A1 | Oxazinobenzothiazine-6,6-dioxide derivatives, their preparation and their use as medicament | PROVESAN S.A. (CH) | 1984-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12084414-B2 | Therapeutic compounds and compositions | KLK5, KLKB1, KLK2 | TP53 3278/4885NPC1 1058/4885RAB9A 2797/4885 |
| US-12486502-B2 | RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use | AGER, ASGR1, TLR3 | TP53 1601/4885NPC1 2762/4885RAB9A 761/4885 |
| US-20260043029-A1 | RNAi Agents for Inhibiting Expression of Thymic Stromal Lymphopoietin (TSLP), Compositions Thereof, and Methods of Use | TSLP, RBM26, TEK | TP53 1071/4885NPC1 3350/4885RAB9A 4366/4885 |
| US-20250214931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | TP53 3278/4885NPC1 1058/4885RAB9A 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.